A Randomized, Double-Blind, Placebo-Controlled Study of a Nutraceutical Supplement for Promoting Hair Growth in Perimenopausal, Menopausal, and Postmenopausal Women With Thinning Hair.
Administration, Oral
Adult
Aged
Alopecia
/ diagnosis
Dermoscopy
/ methods
Dietary Supplements
/ adverse effects
Double-Blind Method
Female
Hair
/ diagnostic imaging
Humans
Menopause
/ physiology
Middle Aged
Photography
Phytochemicals
/ administration & dosage
Placebos
/ administration & dosage
Surveys and Questionnaires
Treatment Outcome
Journal
Journal of drugs in dermatology : JDD
ISSN: 1545-9616
Titre abrégé: J Drugs Dermatol
Pays: United States
ID NLM: 101160020
Informations de publication
Date de publication:
01 01 2021
01 01 2021
Historique:
entrez:
5
1
2021
pubmed:
6
1
2021
medline:
8
6
2021
Statut:
ppublish
Résumé
Hair loss is a complex and multi-factorial problem that is associated with significant psychological morbidity in women. Menopausal women represent a significant percentage of those affected, since the menopausal hormonal transition can be a contributing factor. A novel nutraceutical supplement has been specifically formulated with phytoactives to improve hair growth and quality in menopausal women (Nutrafol® Women’s Balance Capsules). The objective of this 6-month, randomized, double-blind, placebo-controlled study was to assess the safety and efficacy of this oral supplement to promote hair growth in perimenopausal, menopausal, and postmenopausal women with self-perceived thinning. Subjects were randomized to the study supplement (n=40) or placebo (n=30). The primary endpoint was a statistically significant increase in the number of terminal and vellus hairs based on phototrichogram analysis. Daily intake of the nutraceutical supplement resulted in progressive and significant increase in terminal and total hair counts on days 90 (P<0.01) and 180 (P<0.01) compared to placebo. The vellus hair counts significantly increased for the active treatment group (P<0.05) by day 180 while significantly decreasing for the placebo group subjects. Hair shedding progressively and significantly decreased for the active group compared to placebo, culminating in a reduction of 32.41% by day 180 (P<0.01). The study supplement was well-tolerated. ClinicalTrials.gov Identifier: NCT04048031
J Drugs Dermatol. 2021;20(1):55-61. doi:10.36849/JDD.5701
THIS ARTICLE HAD BEEN MADE AVAILABLE FREE OF CHARGE. PLEASE SCROLL DOWN TO ACCESS THE FULL TEXT OF THIS ARTICLE WITHOUT LOGGING IN. NO PURCHASE NECESSARY. PLEASE CONTACT THE PUBLISHER WITH ANY QUESTIONS.
Identifiants
pubmed: 33400421
pii: S1545961621P0055X
doi: 10.36849/JDD.5701
doi:
Substances chimiques
Phytochemicals
0
Placebos
0
Banques de données
ClinicalTrials.gov
['NCT04048031']
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM